Cardio and Renovascular Effects of Isometric Exercise in the Healthy Human Measured by PET/CT and MRI
1 other identifier
interventional
10
1 country
1
Brief Summary
This randomized crossover study aims to validate measurements of renal perfusion in healthy males with PET/CT, using 15-oxygen labeled water as tracer, against the validated multiparametric MRI technique. The study will determine:
- Total renal blood flow and regional renal perfusion at baseline (rest) and during isometric muscle exercise of the upper arm, using PET/CT (with 15-oxygen labeled water as a tracer) and MRI.
- The coefficient of variation of renal blood flow and regional renal perfusion measurements at baseline and during isometric muscle exercise of the upper arm, using PET/CT (with 15-oxygen labeled water as a tracer) and MRI.
- Regional renal oxygenation and oxygen extraction at baseline and during isometric muscle exercise of the upper arm using MRI.
- The coefficient of variation on regional renal oxygenation and oxygen extraction measurements at baseline and during isometric muscle exercise of the upper arm using MRI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 7, 2024
CompletedFirst Submitted
Initial submission to the registry
August 7, 2024
CompletedFirst Posted
Study publicly available on registry
August 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedAugust 15, 2024
August 1, 2024
7 months
August 7, 2024
August 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Coefficient of variation on total blood flow and regional renal perfusion measurements at rest and during isometric muscle exercise, measured by PET/CT with 15-Oxygen labeled water and MRI
No metric unit
Each participant's study day during the span of the study (approximately 5 months)
Total blood flow at rest and during isometric muscle exercise measured by PET/CT with 15-Oxygen labeled water and MRI
Volume of blood pr unit time, ml/min
Each participant's study day during the span of the study (approximately 5 months)
Regional renal perfusion at rest and during isometric muscle exercise measured by PET/CT with 15-Oxygen labeled water and MRI
Volume of blood pr unit time pr unit tissue mass, ml/min/g
Each participant's study day during the span of the study (approximately 5 months)
Regional renal oxygenation at rest and during isometric muscle exercise using MRI
Percentage, fraction
Each participant's study day during the span of the study (approximately 5 months)
Regional renal extraction of oxygen at rest and during isometric muscle exercise using MRI
Percentage, fraction
Each participant's study day during the span of the study (approximately 5 months)
Coefficient of variation on regional renal oxygenation and extraction of oxygen measurements at rest and isometric muscle exercise using MRI
No metric unit
Each participant's study day during the span of the study (approximately 5 months)
Study Arms (2)
Group randomized to begin with MRI
OTHERGroup is randomized to begin with MRI and have PET/CT performed later on the same day
Group randomized to begin with PET/CT
OTHERGroup is randomized to begin with PET/CT and have MRI performed later on the same day
Interventions
Eligibility Criteria
You may qualify if:
- Normal health stated through medical questionnaire, examination and blood samples.
You may not qualify if:
- Immunosuppressive treatment
- Alcohol abuse
- Treatment with glucocorticoids, Glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4)-inhibitors
- Medical treatment affecting insulin secretion or cardiovascular endpoints
- Liver disease
- Decreased kidney function
- Severe claustrophobia
- Elements incompatible with MR.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bispebjerg Hospital, Department of Clinical Physiology & Nuclear Medicine
Copenhagen, Capital Region, 2400, Denmark
Study Officials
- PRINCIPAL INVESTIGATOR
Ali Asmar, MD, PhD
Bispebjerg Hospital, Department of Clinical Physiology and Nuclear Medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Physician, Associate Professor
Study Record Dates
First Submitted
August 7, 2024
First Posted
August 15, 2024
Study Start
May 7, 2024
Primary Completion
December 1, 2024
Study Completion
December 1, 2024
Last Updated
August 15, 2024
Record last verified: 2024-08